No Appeal: Eloxatin Decision Gives District Courts Primacy On 30-Month Stays
Executive Summary
Brand companies have fewer tools to fight off generic challenges following a ruling that prevents them from reinstating a 30-month stay on FDA approvals if they initially lose the patent case in district court
You may also be interested in...
FDA Hit With Slew Of Suits As Firms Fight For Market Advantage
At least nine complaints have been filed against the agency since March, most involving market exclusivity claims; lawyers expect innovators will be pursuing more cases as patents expire and biosimilars emerge.
Lovenox Lawsuit May Be Omen For Biosimilar Battles
Sanofi-Aventis' suit against FDA seeking to overturn its approval of generic Lovenox (enoxaparin) is a harbinger of what the agency will face once it approves follow-on biologics
Lovenox Lawsuit May Be Omen For Biosimilar Battles
Sanofi-Aventis' suit against FDA seeking to overturn its approval of generic Lovenox (enoxaparin) is a harbinger of what the agency will face once it approves follow-on biologics